CN115380049B - 对生理性铁过载的治疗 - Google Patents

对生理性铁过载的治疗

Info

Publication number
CN115380049B
CN115380049B CN202080094612.5A CN202080094612A CN115380049B CN 115380049 B CN115380049 B CN 115380049B CN 202080094612 A CN202080094612 A CN 202080094612A CN 115380049 B CN115380049 B CN 115380049B
Authority
CN
China
Prior art keywords
leu
nori
gly
val
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080094612.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN115380049A (zh
Inventor
M·韦克
V·伽玛谢夫斯基
I·瑟尔
J·L·帕普沃思
D·梅纳德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kemab Co ltd
Original Assignee
Kemab Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1917524.9A external-priority patent/GB201917524D0/en
Priority claimed from GBGB1917882.1A external-priority patent/GB201917882D0/en
Application filed by Kemab Co ltd filed Critical Kemab Co ltd
Priority to CN202610300351.7A priority Critical patent/CN122427287A/zh
Publication of CN115380049A publication Critical patent/CN115380049A/zh
Application granted granted Critical
Publication of CN115380049B publication Critical patent/CN115380049B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogen, Water And Hydrids (AREA)
  • Treatment Of Water By Oxidation Or Reduction (AREA)
  • Reciprocating, Oscillating Or Vibrating Motors (AREA)
CN202080094612.5A 2019-11-29 2020-11-27 对生理性铁过载的治疗 Active CN115380049B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202610300351.7A CN122427287A (zh) 2019-11-29 2020-11-27 对生理性铁过载的治疗

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1917524.9 2019-11-29
GBGB1917524.9A GB201917524D0 (en) 2019-11-29 2019-11-29 Treatment for physiological iron overload
GB1917882.1 2019-12-06
GBGB1917882.1A GB201917882D0 (en) 2019-12-06 2019-12-06 Treatment for physiological iron overload
PCT/EP2020/083677 WO2021105389A1 (en) 2019-11-29 2020-11-27 Treatment for physiological iron overload

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202610300351.7A Division CN122427287A (zh) 2019-11-29 2020-11-27 对生理性铁过载的治疗

Publications (2)

Publication Number Publication Date
CN115380049A CN115380049A (zh) 2022-11-22
CN115380049B true CN115380049B (zh) 2026-03-27

Family

ID=73698783

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080094612.5A Active CN115380049B (zh) 2019-11-29 2020-11-27 对生理性铁过载的治疗
CN202610300351.7A Pending CN122427287A (zh) 2019-11-29 2020-11-27 对生理性铁过载的治疗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202610300351.7A Pending CN122427287A (zh) 2019-11-29 2020-11-27 对生理性铁过载的治疗

Country Status (12)

Country Link
US (1) US12570740B2 (enExample)
EP (1) EP4065607A1 (enExample)
JP (2) JP7709436B2 (enExample)
KR (1) KR20220107252A (enExample)
CN (2) CN115380049B (enExample)
BR (1) BR112022010424A2 (enExample)
CA (1) CA3162880A1 (enExample)
CO (1) CO2022009078A2 (enExample)
IL (1) IL293314A (enExample)
MX (1) MX2022006495A (enExample)
PH (1) PH12022551299A1 (enExample)
WO (1) WO2021105389A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021251087A1 (en) * 2020-04-07 2022-12-01 Mabwell Therapeutics Inc. Anti-TMPRSS6 antibodies and uses thereof
WO2022240877A1 (en) 2021-05-11 2022-11-17 Regeneron Pharmaceuticals, Inc. Anti-tmprss6 antibodies and uses thereof
CN113667600B (zh) * 2021-07-21 2023-08-11 青岛海特生物医疗有限公司 用于二氧化碳培养箱功率分配的方法、装置及二氧化碳培养箱
WO2026019448A1 (en) * 2024-07-16 2026-01-22 Rallybio Ipe Llc Treatment of pathologies associated with beta-thalassemia

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105219780A (zh) * 2015-10-30 2016-01-06 中国人民解放军第三军医大学第一附属医院 抗多亚基因型hcv抗体基因r3-19及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
WO2005023835A2 (en) * 2003-09-09 2005-03-17 Irm Llc Modulators of transmembrane protease serine 6
GB0614201D0 (en) * 2006-07-18 2006-08-23 Univ Cardiff Matriptase-2
CA2672758C (en) 2006-12-18 2019-07-30 Acceleron Pharma Inc. Activin-actrii antagonists and uses for increasing red blood cell levels
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
DK3241435T3 (da) 2009-07-08 2021-08-23 Kymab Ltd Dyremodeller og terapeutiske molekyler
CN103228130B (zh) 2010-06-17 2016-03-16 科马布有限公司 动物模型及治疗分子
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
WO2016071701A1 (en) * 2014-11-07 2016-05-12 Kymab Limited Treatment of disease using ligand binding to targets of interest
WO2016085852A1 (en) 2014-11-24 2016-06-02 Alnylam Pharmaceuticals, Inc. Tmprss6 irna compositions and methods of use thereof
AU2016302768B2 (en) * 2015-07-31 2019-08-22 Medimmune Limited Methods for treating hepcidin-mediated disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105219780A (zh) * 2015-10-30 2016-01-06 中国人民解放军第三军医大学第一附属医院 抗多亚基因型hcv抗体基因r3-19及其应用

Also Published As

Publication number Publication date
EP4065607A1 (en) 2022-10-05
CN115380049A (zh) 2022-11-22
CA3162880A1 (en) 2021-06-03
JP7709436B2 (ja) 2025-07-16
JP2023503513A (ja) 2023-01-30
BR112022010424A2 (pt) 2022-08-23
PH12022551299A1 (en) 2023-11-20
JP7862652B2 (ja) 2026-05-19
JP2025166832A (ja) 2025-11-06
IL293314A (en) 2022-07-01
KR20220107252A (ko) 2022-08-02
MX2022006495A (es) 2022-09-07
CO2022009078A2 (es) 2022-09-20
CN122427287A (zh) 2026-07-21
US20230025129A1 (en) 2023-01-26
US12570740B2 (en) 2026-03-10
WO2021105389A1 (en) 2021-06-03

Similar Documents

Publication Publication Date Title
KR102473028B1 (ko) 항-tim-3 항체 및 조성물
KR102697797B1 (ko) 위 저해 펩타이드 수용체(gipr)에 대한 길항제에 접합된 glp-1 수용체 작용제를 사용하여 대사 장애를 치료 또는 개선하는 방법
KR102737715B1 (ko) Pd-1, tim-3 및 lag-3을 표적화하는 조합 요법
KR101865974B1 (ko) β-ＫＬＯＴＨＯ, ＦＧＦ 수용체 및 이들의 복합체에 결합하는 인간 항원 결합 단백질
AU2021254602A1 (en) Humanized anti-MUC1* antibodies
TWI891060B (zh) 編碼胃抑肽受體（ｇｉｐｒ）特異性抗體之核酸分子及製造該抗體之方法
DK2379594T3 (en) Human CGRP receptor binding antibodies
KR102604433B1 (ko) 항-icos 항체
KR102933484B1 (ko) 항-il-27 항체 및 그의 용도
CN107207604A (zh) 抗alk2抗体
AU2019348815B2 (en) Antagonists
CN115380049A (zh) 对生理性铁过载的治疗
KR20230165285A (ko) Gdf15 신호전달의 치료적 억제제
KR20240017054A (ko) 항-icos 항체를 사용한 pd-l1 음성 또는 저발현 암의 치료
KR102880176B1 (ko) Apj 항체 및 이와 엘라벨라의 융합 단백질, 및 그의 약학 조성물 및 적용
RU2795232C2 (ru) Комбинированные лекарственные средства, нацеленные на pd-1, tim-3 и lag-3
CN117916262A (zh) Gdf15信号传导的治疗性抑制剂
HK40082642A (en) Combination therapies targeting pd-1, tim-3, and lag-3
KR20240007760A (ko) 항-icos 항체의 용도
HK40003736B (en) Anti-icos antibodies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant